|
|
|
|
|
|
| Abstract Search | Browse Program and Abstracts | Schedule-at-a-Glance | Conference Mission & Sponsors | Program Committee | Contact Us |
| # | Title |
|---|---|
| 232 | Cytokine Adjuvants for the Induction of Anti-HIV Mucosal IgA and Cell-Mediated Immune Responses
H. Staats*, T. Tlusty, G. Sempowski, H.-X. Liao, and B. Haynes Duke Univ. Med. Ctr., Durham, NC, USA |
| 233 | Mucosal Immunization with Whole-Killed Human Immunodeficiency Virus Type 1 (HIV-1) Immunogen (Remune) Plus CpG ODN Increases IgA and Immune Responses in the Genital Tract
N. Dumais*1, R. B. Moss2, H. L. Davis3, and K. L. Rosenthal1 1Ctr. for Gene Therapeutics, McMaster Univ., Hlth. Sci. Ctr., Hamilton, Ontario, Canada; 2The Immune Response Corp., Carlsbad, CA, USA; and 3Coley Pharmaceutical Group, Ottawa, Canada |
| 234 | Development of a Controlled-Release HIV Vaccine Adjuvant
T. Castor* and P. O. Ilyinskii Aphios Corp., Woburn, MA, USA |
| 235 | CpG Overcomes the Th2 Biased Immune Profile in Schistosoma-Infected Mice to Generate Th1 Type HIV-1-Specific Immune Responses to Remune-Relevance to AIDS Vaccines in Developing Countries
M. Ayash-Rashkovsky1 , Z. Weisman1, G. Borkow1, R. Moss2, and Z. Bentwich1* 1Hebrew Univ. Hadassah Med. Sch., Rehovot, Israel and 2Immune Response Corp., San Diego, CA, USA |